The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Ipilimumab plus Nivolumab for Malignant Pleural Mesothelioma

Dual immune checkpoint blockade with ipilimumab and nivolumab as first-line treatment for unresectable malignant pleural mesothelioma

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Ipilimumab plus Nivolumab for Malignant Pleural Mesothelioma?

Ipilimumab plus nivolumab combination provides first-line immunotherapy for malignant pleural mesothelioma.

CheckMate 743 trial demonstrated overall survival benefit versus platinum-pemetrexed chemotherapy.

Dual checkpoint blockade combines anti-CTLA-4 ipilimumab with anti-PD-1 nivolumab.

Benefit most pronounced in non-epithelioid sarcomatoid and biphasic histology.

Treatment continues for two years total with 21-day cycles.

Symptoms

Immune-related adverse events including pneumonitis, colitis, hepatitis, endocrinopathies require monitoring.
Severe pneumonitis is potentially life-threatening requiring imaging and immediate treatment.
Colitis with diarrhea requires steroid therapy and infection workup.
Hepatitis with transaminase elevation requires monitoring with steroid therapy when severe.
Endocrinopathies including thyroid dysfunction, hypophysitis, adrenal insufficiency require hormone replacement.

Risk Factors

Asbestos exposure represents primary etiologic factor in pleural mesothelioma development.
Occupational exposure including shipyard work, construction, mining contributes to mesothelioma risk.
Latency period of 20-40 years between asbestos exposure and mesothelioma diagnosis.
Erionite exposure in certain geographic regions causes mesothelioma without asbestos.
BAP1 germline mutations associate with mesothelioma and other cancer susceptibility.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Mesothelioma diagnosis warrants specialized thoracic oncology center evaluation for treatment planning.
  • Severe respiratory symptoms, hemoptysis, severe pleural effusion require urgent evaluation.
  • Multidisciplinary care including thoracic oncology, surgery, radiation, palliative care essential.
  • Immune-related adverse events including respiratory, gastrointestinal, hepatic, endocrine symptoms warrant urgent assessment.
  • Disease progression on immunotherapy warrants chemotherapy or clinical trial consideration.

Treatment Methods

01
Ipilimumab 1 mg/kg every 6 weeks plus nivolumab 360 mg every 3 weeks for two years.
02
Comprehensive baseline evaluation including thyroid, adrenal, liver function, ECG, autoimmune screening.
03
Active surveillance for immune-related adverse events with prompt management when occurring.
04
Pleurodesis or pleural catheter for symptomatic pleural effusions improving quality of life.
05
Comprehensive multidisciplinary care with thoracic oncology, surgery, radiation oncology, palliative care, asbestos exposure history documentation, immune-related adverse event protocols, dose modifications and treatment interruptions when needed, treatment continuation despite some immune-related events with appropriate management, response assessment with imaging every 9-12 weeks, clinical trial enrollment for progression, palliative interventions for symptom management, and survivorship and end-of-life care planning provides optimal outcomes for patients with malignant pleural mesothelioma.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.